X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA ABBOTT INDIA SHASUN PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 123.9 39.1 317.0% View Chart
P/BV x 8.5 10.1 84.9% View Chart
Dividend Yield % 0.2 0.7 34.0%  

Financials

 SHASUN PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
ABBOTT INDIA
Mar-18
SHASUN PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs946,110 1.5%   
Low Rs463,996 1.1%   
Sales per share (Unadj.) Rs214.21,552.2 13.8%  
Earnings per share (Unadj.) Rs5.3188.8 2.8%  
Cash flow per share (Unadj.) Rs15.8196.4 8.1%  
Dividends per share (Unadj.) Rs1.0055.00 1.8%  
Dividend yield (eoy) %1.41.1 131.4%  
Book value per share (Unadj.) Rs53.3796.6 6.7%  
Shares outstanding (eoy) m56.6221.25 266.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.3 10.0%   
Avg P/E ratio x13.126.8 48.9%  
P/CF ratio (eoy) x4.425.7 17.2%  
Price / Book Value ratio x1.36.3 20.7%  
Dividend payout %18.729.1 64.3%   
Avg Mkt Cap Rs m3,958107,376 3.7%   
No. of employees `000NA3.3 0.0%   
Total wages/salary Rs m2,1643,937 55.0%   
Avg. sales/employee Rs ThNM9,929.3-  
Avg. wages/employee Rs ThNM1,185.1-  
Avg. net profit/employee Rs ThNM1,207.7-  
INCOME DATA
Net Sales Rs m12,12732,985 36.8%  
Other income Rs m2291,170 19.6%   
Total revenues Rs m12,35634,155 36.2%   
Gross profit Rs m1,0095,245 19.2%  
Depreciation Rs m594162 366.6%   
Interest Rs m41538 1,086.6%   
Profit before tax Rs m2306,215 3.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-732,203 -3.3%   
Profit after tax Rs m3024,012 7.5%  
Gross profit margin %8.315.9 52.3%  
Effective tax rate %-31.735.4 -89.3%   
Net profit margin %2.512.2 20.5%  
BALANCE SHEET DATA
Current assets Rs m6,88422,655 30.4%   
Current liabilities Rs m8,4566,681 126.6%   
Net working cap to sales %-13.048.4 -26.8%  
Current ratio x0.83.4 24.0%  
Inventory Days Days6265 95.1%  
Debtors Days Days10829 368.9%  
Net fixed assets Rs m4,970835 594.9%   
Share capital Rs m113213 53.3%   
"Free" reserves Rs m2,87516,715 17.2%   
Net worth Rs m3,02016,928 17.8%   
Long term debt Rs m1,8170-   
Total assets Rs m13,34724,162 55.2%  
Interest coverage x1.6163.7 0.9%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.91.4 66.6%   
Return on assets %5.416.8 32.1%  
Return on equity %10.023.7 42.2%  
Return on capital %13.336.9 36.1%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,843369 1,585.3%   
Fx outflow Rs m2,1733,807 57.1%   
Net fx Rs m3,669-3,438 -106.7%   
CASH FLOW
From Operations Rs m3981,527 26.0%  
From Investments Rs m-1,635-2,148 76.1%  
From Financial Activity Rs m1,309-1,024 -127.8%  
Net Cashflow Rs m71-1,646 -4.3%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.6 7.9 45.6%  
FIIs % 17.6 0.1 17,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 17.1 231.6%  
Shareholders   20,750 18,270 113.6%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   NOVARTIS  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  IPCA LABS  NATCO PHARMA  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Weak; FMCG Stocks Drag(12:30 pm)

Stock markets in India are trading in negative territory weighed by fast-moving consumer goods (FMCG) stocks.

Related Views on News

BIOCON LTD at All Time High; BSE HEALTHCARE Index Up 0.6% (Market Updates)

Sep 26, 2018 | Updated on Sep 26, 2018

BIOCON LTD share price has hit an all time high at Rs 718 (up 0.4%). The BSE HEALTHCARE Index is up by 0.6%. Among the top gainers in the BSE HEALTHCARE Index today are BIOCON LTD (up 0.4%) and DR. REDDYS LAB (up 0.3%). The top losers include APOLLO HOSPITALS and SYNGENE INTERNATIONAL .

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Up 1.3% (Market Updates)

Sep 26, 2018 | Updated on Sep 26, 2018

DIVIS LABORATORIES share price has hit an all time high at Rs 1,409 (up 1.5%). The BSE HEALTHCARE Index is up by 1.3%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 1.5%) and ABBOTT INDIA (up 0.7%). The top losers include ALEMBIC PHARMA (down 0.1%) and ERIS LIFESCIENCES LIMITED (down 0.1%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS